Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT

Key Points

• Dimensional Fund Advisors increased its 4D Molecular Therapeutics position by 77.3% in the first quarter, purchasing 227,982 shares and bringing its ownership to 522,823 shares, or 1.0% of the company. Institutional investors collectively own 99.27% of FDMT.
• Analyst sentiment is generally positive: FDMT has an average “Moderate Buy” rating and a consensus price target of $29.75, despite some sell ratings. B. Riley and HC Wainwright assigned price targets of $37 and $36, respectively.
• FDMT opened at $11.47, with a market capitalization of approximately $599.7 million and a 52-week range of $5.46 to $14.00. Insiders sold 197,226 shares worth about $2.2 million during the latest quarter.

Dimensional Fund Advisors LP lifted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 77.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 522,823 shares of the company's stock after purchasing an additional 227,982 shares during the quarter. Dimensional Fund Advisors LP owned 1.00% of 4D Molecular Therapeutics worth $4,863,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new position in 4D Molecular Therapeutics during the first quarter valued at approximately $39,000. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $41,000. AQR Capital Management LLC bought a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth approximately $46,000. Daiwa Securities Group Inc. boosted its stake in shares of 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company's stock valued at $48,000 after purchasing an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $48,000. 99.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on FDMT. Wall Street Zen cut shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. B. Riley Financial initiated coverage on shares of 4D Molecular Therapeutics in a research report on Friday, July 31st. They set a "buy" rating and a $37.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Chardan Capital upgraded 4D Molecular Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.75.

4D Molecular Therapeutics Stock Performance

FDMT opened at $11.47 on Wednesday. The stock's 50 day moving average price is $10.79 and its 200-day moving average price is $9.80. 4D Molecular Therapeutics, Inc. has a 52-week low of $5.46 and a 52-week high of $14.00. The stock has a market capitalization of $599.65 million, a PE ratio of -4.46 and a beta of 2.73.

Insider Activity

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the sale, the insider directly owned 8,617 shares of the company's stock, valued at approximately $103,404. The trade was a 53.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the sale, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 197,226 shares of company stock worth $2,200,677 in the last quarter. 7.90% of the stock is owned by corporate insiders.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

Want to see what other hedge funds are holding FDMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source